Fresenius Kabi Oncology’s (FKOL) promoter entity Fresenius Kabi (Singapore) (FKSL) is planning to delist its Indian arm through acquiring 19% stake held by the public. FKSL intends to pay an indicative price of upto Rs 130 per share to acquire the scrips offered to it in the delisting offer.
Fresenius Kabi (Singapore) holds 81% of the total stake in the Indian arm.
Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.
